Copyright
©The Author(s) 2019.
World J Clin Cases. Feb 6, 2019; 7(3): 260-269
Published online Feb 6, 2019. doi: 10.12998/wjcc.v7.i3.260
Published online Feb 6, 2019. doi: 10.12998/wjcc.v7.i3.260
Table 4 Overall survival and (number of patients at risk) at 6, 12 and 36 mo
| mean survival | OS 6 mo | OS 1 yr | OS 3 yr | |
| HSP27 (72) | ||||
| Low (23) | 49 | 91.3% (21) | 60.9% (14) | 39.1% (9) |
| High (49) | 23 | 69.4% (34) | 44.9% (22) | 16.3% (8) |
| HSP70 (76) | ||||
| Low (49) | 40 | 87.8% (43) | 61.2% (30) | 30.6% (15) |
| High (27) | 17 | 59.3% (16) | 33.3% (9) | 11.1% (3) |
- Citation: Söderström HK, Kauppi JT, Oksala N, Paavonen T, Krogerus L, Räsänen J, Rantanen T. Overexpression of HSP27 and HSP70 is associated with decreased survival among patients with esophageal adenocarcinoma. World J Clin Cases 2019; 7(3): 260-269
- URL: https://www.wjgnet.com/2307-8960/full/v7/i3/260.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i3.260